This page exists because HBOT marketing routinely cites only the positive half of the literature. Here is the whole shape of it.
The full ledger
- Where evidence is established: the FDA-cleared indication list — settled, uncontroversial, and distinct from neurological-recovery claims.
- Where trials are positive: under clinical-director review — specific trials, with populations and effect sizes, will be cited here from the approved bibliography.
- Where trials are null: the same review will cite the null and sham-controlled trials with equal prominence — the sham-effect literature is part of the story.
- What that mix means: the effect of pressurized oxygen on neurological recovery remains genuinely contested in the literature — which is why we treat HBOT as an adjunct under measurement, never a headline therapy, and why our own patients' re-test data governs its use in their plan.
Our operating posture
Evidence-informed adjunct within measured programs; candidacy clinical; claims limited to what the cited record supports; and this page updates as the literature does — with revision dates shown. Last reviewed: September 22, 2026.
FAQ (2): Does HBOT cure concussion/TBI? (No responsible reading of the literature supports "cure" — and we don't.) · Why offer it at all? (Where the positive-trial signal, patient specifics, and measurement discipline align, an adjunct with plausible mechanism and manageable risk can earn a supervised place — earn being the operative word.)
Wondering whether HBOT belongs in your plan? That's decided from your data, never as a standalone course — start with a free 15-minute call.